Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study
- 18 July 2018
- journal article
- research article
- Published by Springer Nature in CNS Drugs
- Vol. 32 (10) , 963-970
Abstract
Two phase III trials have demonstrated the clinical and radiological efficacy of delayed-release dimethyl fumarate (DMF) in relapsing-remitting multiple sclerosis (RRMS). However, data on its safety and effectiveness in real-world practice are still limited.Keywords
This publication has 22 references indexed in Scilit:
- Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte countMultiple Sclerosis and Related Disorders, 2018
- Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 casesJournal of Neurology, 2017
- Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte countMultiple Sclerosis Journal, 2017
- Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational studyJournal of Neurology, 2016
- Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MSNeurology Clinical Practice, 2016
- Time course of clinical and neuroradiological effects of delayed‐release dimethyl fumarate in multiple sclerosisEuropean Journal of Neurology, 2015
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple SclerosisNew England Journal of Medicine, 2012
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathwayBrain, 2011
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patientsAnnals of Neurology, 2006